O
Orly Dym
Researcher at Weizmann Institute of Science
Publications - 81
Citations - 6321
Orly Dym is an academic researcher from Weizmann Institute of Science. The author has contributed to research in topics: Biology & Protein structure. The author has an hindex of 31, co-authored 69 publications receiving 5269 citations.
Papers
More filters
Journal ArticleDOI
Kemp elimination catalysts by computational enzyme design
Daniela Röthlisberger,Olga Khersonsky,Andrew M. Wollacott,Lin Jiang,Jason DeChancie,Jamie L. Betker,Jasmine L. Gallaher,Eric A. Althoff,Alexandre Zanghellini,Orly Dym,Shira Albeck,Kendall N. Houk,Dan S. Tawfik,David Baker +13 more
TL;DR: The computational design of eight enzymes that use two different catalytic motifs to catalyse the Kemp elimination—a model reaction for proton transfer from carbon—with measured rate enhancements of up to 105 and multiple turnovers are described.
Journal ArticleDOI
Protein production and purification.
Susanne Gräslund,Pär Nordlund,J Weigelt,B M Hallberg,James E. Bray,Opher Gileadi,Stefan Knapp,Udo Oppermann,Cheryl H. Arrowsmith,Raymond Hui,J Ming,Sirano Dhe-Paganon,Park H-W.,Alexei Savchenko,Adelinda Yee,Aled M. Edwards,Renaud Vincentelli,Christian Cambillau,R Kim,Kim S-H.,Zihe Rao,Yunyu Shi,Thomas C. Terwilliger,Kim C-Y.,Hung L-W.,Geoffrey S. Waldo,Yoav Peleg,Shira Albeck,Tamar Unger,Orly Dym,Jaime Prilusky,Joel L. Sussman,Raymond C. Stevens,Scott A. Lesley,Scott A. Lesley,Ian A. Wilson,Ian A. Wilson,Andrzej Joachimiak,Frank R. Collart,Irina Dementieva,Mark I. Donnelly,William H. Eschenfeldt,Youngchang Kim,Lucy Stols,Ruiying Wu,M. Zhou,Stephen K. Burley,J.S. Emtage,J.M. Sauder,D.A. Thompson,Kevin Bain,John G. Luz,Tarun Gheyi,F Zhang,Shane Atwell,Steven C. Almo,Jeffrey B. Bonanno,Andras Fiser,Soumya Swaminathan,F.W. Studier,Mark R. Chance,Andrej Sali,Thomas Acton,Rong Xiao,L Zhao,L C Ma,John F. Hunt,Liang Tong,Kellie Cunningham,Masayori Inouye,Stephen Anderson,Haleema Janjua,Ritu Shastry,C K Ho,D Wang,Hao Wang,M Jiang,Gaetano T. Montelione,David I. Stuart,Raymond J. Owens,S Daenke,Anja Schütz,Udo Heinemann,S Yokoyama,Konrad Büssow,Kristin C. Gunsalus,Kristin C. Gunsalus +86 more
TL;DR: This review presents methods that could be applied at the outset of any project, a prioritized list of alternate strategies and a list of pitfalls that trip many new investigators.
Journal ArticleDOI
Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system
Yoseph Shaaltiel,Daniel Bartfeld,Sharon Hashmueli,Gideon Baum,Einat Brill-Almon,Gad Galili,Orly Dym,Swetlana Boldin-Adamsky,Israel Silman,Joel L. Sussman,Anthony H. Futerman,David Aviezer +11 more
TL;DR: The production of a recombinant human GCD in a carrot cell suspension culture shows a level of biological activity similar to that of Cerezyme produced in CHO cells, as well as a highly homologous high-resolution three-dimensional structure, determined by X-ray crystallography, indicating the potential safety of prGCD.
Journal ArticleDOI
Automated Structure- and Sequence-Based Design of Proteins for High Bacterial Expression and Stability.
Adi Goldenzweig,Moshe Goldsmith,Shannon E. Hill,Or Gertman,Paola Laurino,Yacov Ashani,Orly Dym,Tamar Unger,Shira Albeck,Jaime Prilusky,Raquel L. Lieberman,Amir Aharoni,Israel Silman,Joel L. Sussman,Dan S. Tawfik,Sarel J. Fleishman +15 more
TL;DR: A computational strategy is developed and designed an AChE variant bearing 51 mutations that improved core packing, surface polarity, and backbone rigidity and obtained enhanced stability and/or higher yields of soluble and active protein in E. coli.
Journal ArticleDOI
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Jiří Zahradník,Shir Marciano,Maya Shemesh,Eyal Zoler,Daniel Harari,Jeanne Chiaravalli,Bjorn Meyer,Yinon Rudich,Chunlin Li,Ira Marton,Orly Dym,Nadav Elad,Mark G. Lewis,Hanne Leth Andersen,Matthew Gagne,Robert A. Seder,Daniel C. Douek,Gideon Schreiber +17 more
TL;DR: It is shown that the high-affinity variant RBD-62 can be used as a drug to inhibit infection with SARS-CoV-2 and variants Alpha, Beta and Gamma in vitro and its structure provides a structural basis for future drug and vaccine development and for in silico evaluation of known antibodies.